Sugi Predict

Sugi Predict / Compounds / SCHEMBL51377

SCHEMBL51377

SCHEMBL51377

NS(=O)(=O)Cc1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 2/20 0.50
▸ CA2 P00918 3/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA5A P35218 2/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ PRMT1 Q99873 1/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ CA7 P43166 1/20 0.45
▸ CA5B Q9Y2D0 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ LIN28A Q9H9Z2 1/20 0.44
▸ GRIN2D O15399 1/20 0.43
▸ GRIN3B O60391 1/20 0.43
▸ GRIN1 Q05586 1/20 0.43
▸ GRIN2A Q12879 1/20 0.43
▸ GRIN2B Q13224 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29596510 1.00 HRH1 (0.50) HRH1CA2CA1CA5ACA9
Hydrochloric Acid SCHEMBL20502503 0.98 HRH1 (0.48) HRH1CA2CA1CA5ACA9
SCHEMBL9600152 0.83 KMT2A (0.50) HRH1L3MBTL1KMT2APRMT1TDP1
SCHEMBL5057906 0.82 PRMT1 (0.38) HRH1CA2CA1CA5ACA9
SCHEMBL5516006 0.81 KMT2A (0.49) HRH1L3MBTL1KMT2APRMT1TDP1
SCHEMBL28641442 0.80 HRH1 (0.52) HRH1L3MBTL1KMT2APRMT1TDP1
SCHEMBL21596180 0.80 L3MBTL1 (0.49) HRH1CA2CA1CA5AL3MBTL1
SCHEMBL4184428 0.80 HRH1 (0.57) HRH1CA2CA1L3MBTL1KMT2A
SCHEMBL1272069 0.79 KMT2A (0.47) HRH1L3MBTL1KMT2APRMT1TDP1
SCHEMBL1272072 0.79 LMNA (0.54) HRH1L3MBTL1KMT2APRMT1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024131893-A1 IRE1α SMALL MOLECULE INHIBITORS SHANGHAI YI ZHONG XING BIOTECHNOLOGY CO., LTD. (CN) 2024-06-27 — — WO claimed
CN-101888999-B Pyridylmethyl-sulfonamide compounds BASF SE 2013-12-11 — — CN claimed
US-8299262-B2 Pyridylmethyl-sulfonamide compounds BASF SE (DE) 2012-10-30 — — US claimed
JP-2011506281-A — — 2011-03-03 — — JP claimed
CN-101888999-A Pyridylmethyl-sulfonamide compounds BASF SE 2010-11-17 — — CN claimed
US-20100249077-A1 Pyridylmethyl-Sulfonamide Compounds BASF SE (DE) 2010-09-30 — — US claimed
EP-2231605-A1 PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS BASF SE (DE) 2010-09-29 — — EP claimed
CN-101600720-A Phosphoinositide 3-kinase inhibitor compounds and using method HOFFMANN LA ROCHE (CH) 2009-12-09 — — CN claimed
WO-2009071449-A1 PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS BASF SE (DE) 2009-06-11 — — WO claimed
WO-2009071448-A1 PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS BASF SE (DE) 2009-06-11 — — WO claimed
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 — — US disclosed
EP-3164415-B1 ANTI- MGLUR2 CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF INST NAT SANTE RECH MED (FR) 2024-10-30 — — EP disclosed
US-20240336590-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY ANNAPURNA BIO, INC. 2024-10-10 — — US disclosed
US-12091425-B2 Compounds that inhibit MCL-1 protein AMGEN INC. (US) 2024-09-17 — — US disclosed
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2024-09-12 — — US disclosed
US-20050176704-A1 Hydroxymorpholinone derivative and medicinal use thereof SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-08-11 — — US disclosed
WO-2005026175-A1 THIENOPYRAZOLES AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 — — WO disclosed
CN-1160348-C Aryl-{4-fluoro-4-[(2-pyridin-2-YL-ethylamino)-methyl]-piperidin-1-yl}-methanone derivatives as 5-HT1 receptor antagonists Ƥ����������ҩƷ��˾ 2004-08-04 — — CN disclosed
US-6767906-B2 INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. NOVARTIS AG (CH) 2004-07-27 — — US disclosed
CN-1325396-A Aryl-{4-fluoro-4-[(2-pyridin-2-YL-ethylamino)-methyl]-piperidin-1-yl}-methanone derivatives as 5-HT1 receptor antagonists PF MEDICAMENT (FR) 2001-12-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176704-A1 Hydroxymorpholinone derivative and medicinal use thereof CAPN1, OPRM1, CAPN2 HRH1 431/4885CA2 1397/4885CA1 3073/4885
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A HRH1 2783/4885CA2 3641/4885CA1 3382/4885
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer TP53, HIF1AN, MDM2 HRH1 1829/4885CA2 535/4885CA1 1069/4885
US-20240336590-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY APLNR, AGTR1, AGTR2 HRH1 1942/4885CA2 849/4885CA1 3222/4885
US-20100249077-A1 Pyridylmethyl-Sulfonamide Compounds CBR3, CBR1, CBS HRH1 964/4885CA2 564/4885CA1 1970/4885
US-12091425-B2 Compounds that inhibit MCL-1 protein MCL1, BCL9, BCL2L1 HRH1 4286/4885CA2 4701/4885CA1 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.